Daily Sepsis Research Analysis
Across sepsis research today: a preclinical study shows a traditional multi-component therapy (Qingwen Baidu Decoction) protects against sepsis-associated acute kidney injury via TLR4/MyD88/NF-κB inhibition and reduced pyroptosis. In pediatrics, rapid BCID2 diagnostics markedly shortened time to appropriate antibiotics in gram-negative bloodstream infections. A retrospective ICU cohort identified albumin-corrected anion gap as a robust, independent mortality predictor in sepsis-associated liver
Summary
Across sepsis research today: a preclinical study shows a traditional multi-component therapy (Qingwen Baidu Decoction) protects against sepsis-associated acute kidney injury via TLR4/MyD88/NF-κB inhibition and reduced pyroptosis. In pediatrics, rapid BCID2 diagnostics markedly shortened time to appropriate antibiotics in gram-negative bloodstream infections. A retrospective ICU cohort identified albumin-corrected anion gap as a robust, independent mortality predictor in sepsis-associated liver injury.
Research Themes
- Mechanism-guided therapies for sepsis-associated organ dysfunction
- Rapid diagnostics and antimicrobial stewardship in pediatric sepsis
- Prognostic biomarkers in sepsis-associated liver injury
Selected Articles
1. Effects of and mechanisms underlying qingwen baidu decoction in sepsis-associated acute kidney injury.
In a CLP-induced SA-AKI mouse model, QWBD reduced mortality, improved renal function (lower BUN/SCr), mitigated tubular injury, inflammation, and pyroptosis, and inhibited the TLR4/MyD88/NF-κB cascade. UPLC-MS/MS and docking highlighted 2,3-dihydrodauriporphine, homochelidonine, and baicalin as key constituents.
Impact: This study provides mechanistic evidence that a multi-component therapy can modulate innate immune signaling and pyroptosis in sepsis-related AKI, identifying candidate active molecules for translation.
Clinical Implications: While preclinical, the data support further development of QWBD or its active constituents as adjuncts to reduce renal injury in sepsis, potentially informing drug discovery targeting TLR4/MyD88/NF-κB and pyroptosis.
Key Findings
- QWBD reduced mortality and improved renal function (lower BUN and SCr) in CLP-induced SA-AKI mice.
- Histology and molecular assays showed decreased tubular injury, inflammation, and pyroptosis.
- Mechanistically, QWBD inhibited the TLR4/MyD88/NF-κB pathway.
- UPLC-MS/MS and docking identified 2,3-dihydrodauriporphine, homochelidonine, and baicalin as key constituents.
Methodological Strengths
- Integrated in vivo (CLP mouse), in vitro validation, network pharmacology, and molecular docking.
- Use of multiple orthogonal assays (histology, IHC, western blot, RT-qPCR) to confirm pathway inhibition.
Limitations
- Preclinical animal and cell models; no human validation or standardized dosing/PK data.
- Complex multi-component decoction limits attribution to single compounds; formulation variability may affect reproducibility.
Future Directions: Isolate and standardize active constituents, perform PK/toxicity and dose–response studies, and advance to early-phase clinical trials in sepsis-associated AKI.
ETHNOPHARMACOLOGICAL RELEVANCE: Despite advances in critical care, sepsis-associated acute kidney injury (SA-AKI) remains a serious illness that has limited treatment options. Qingwen Baidu Decoction (QWBD) is a prominent traditional Chinese medicine (TCM) formulation; it is widely used in infectious disease management. Nevertheless, its therapeutic impact on SA-AKI and the underlying mechanisms of action are markedly unexplored. OBJECTIVE: This study seeks to integrate molecular docking along with network pharmacology and both cellular and animal experiments to explore the therapeutic utility of QWBD in SA-AKI and provide additional information on its mechanisms. MATERIALS AND METHODS: Renoprotective actions of QWBD were investigated in a cecal ligation and puncture (CLP)-induced SA-AKI mice model. Outcomes consisted of mouse status, survival rate, serum creatinine (SCr) levels, renal tubular histopathology, blood urea nitrogen (BUN) levels, and apoptosis. Renal inflammation and pyroptosis were evaluated through immunohistochemistry, western blotting, and reverse transcription quantitative polymerase chain reaction. QWBD elements and possible targets were determined through ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS). Furthermore, enrichment analyses elucidated the potential mechanisms. In vitro as well as in vivo tests affirmed the involved pathways. Additionally, molecular docking was conducted to identify key active monomeric compounds within QWBD that may exert protective effects.
2. Impact of the BioFire® BCID2 panel on antimicrobial treatment and mortality in pediatric gram-negative bloodstream infections.
In 97 pediatric gram-negative BSI episodes, BCID2 implementation reduced time to appropriate therapy by a median 55.1 hours and led to antimicrobial modification in 78.9% of cases, often guided by resistance gene detection; 7-day mortality did not differ.
Impact: Demonstrates real-world clinical process improvements from rapid diagnostics in pediatric sepsis care, supporting antimicrobial stewardship without apparent early mortality benefit.
Clinical Implications: Adopting BCID2 can expedite targeted therapy and de-escalation (e.g., stop unnecessary glycopeptides), potentially reducing toxicity, resistance selection, and costs in pediatric sepsis management.
Key Findings
- BCID2 reduced time to appropriate antimicrobial therapy by a median 55.1 hours (p < 0.01).
- Antimicrobial regimens were modified in 78.9% of cases, with 42.1% driven by resistance gene results.
- Glycopeptide use was discontinued in 28.9% following BCID2 results.
- No significant difference in 7-day mortality between BCID2 and pre-BCID2 groups.
Methodological Strengths
- Clear pre/post implementation comparison with clinically meaningful process endpoints.
- Granular reporting of resistance gene–guided modifications and de-escalation metrics.
Limitations
- Nonrandomized pre/post design susceptible to secular trends and confounding.
- Modest sample size limits power to detect mortality differences; single-center setting likely.
Future Directions: Conduct multicenter pragmatic trials assessing clinical outcomes, stewardship metrics, and cost-effectiveness; integrate rapid diagnostics with protocolized antimicrobial pathways.
PURPOSE: Rapid molecular diagnostics, such as the BioFire® BCID2 Panel, may improve clinical outcomes by facilitating earlier pathogen identification and antimicrobial stewardship. This study evaluates the impact of BCID2 implementation on antimicrobial treatment and mortality in pediatric Gram-negative Bloodstream infections (BSI). METHODS: Pediatric patients with microbiologically confirmed Gram-negative BSI were divided into two groups: the pre-BCID2 group (diagnosed using conventional blood cultures) and the BCID2 group (diagnosed using the BCID2 Panel). Primary outcomes included time to pathogen identification and antimicrobial treatment modifications. Secondary outcomes included 7-day and 30-day mortality rates. RESULTS: A total of 97 Gram-negative BSI episodes were analyzed (pre-BCID2: 59, BCID2: 38). The BCID2 panel significantly reduced the time to appropriate antimicrobial therapy (median reduction: 55.1 h, p < 0.01). Antimicrobial treatment was modified in 78.9 % of cases following BCID2 results, with 42.1 % requiring changes due to resistance gene detection. Glycopeptide use was discontinued in 28.9 %. The 7-day mortality rate was 10.5 % in the BCID2 group versus 8.5 % in the pre-BCID2 group (p > 0.05). CONCLUSIONS: The BCID2 panel significantly accelerated pathogen and resistance gene identification, leading to improved appropriate antimicrobial usage in pediatric Gram-negative BSI.
3. Prognostic value of albumin-corrected anion gap in critically ill patients with sepsis-associated liver injury: a retrospective study.
Among 443 ICU patients with SALI, higher admission ACAG independently predicted increased ICU, in-hospital, 14-, 28-, and 90-day mortality with a linear dose-response. Associations were consistent across subgroups with multivariable Cox adjustment.
Impact: Identifies a readily available metabolic marker (ACAG) as a robust, independent prognostic indicator in SALI, supporting immediate risk stratification using routine labs.
Clinical Implications: Incorporating ACAG into early assessment of SALI may refine prognostication and triage, prompt closer monitoring, and inform discussions about goals of care.
Key Findings
- Higher ACAG was associated with significantly increased ICU, in-hospital, 14-, 28-, and 90-day mortality (all P < 0.001).
- There was a significant linear dose–response relationship between ACAG and mortality.
- Associations remained consistent across subgroups and in multivariable Cox models.
Methodological Strengths
- Use of multivariable Cox regression and restricted cubic splines to characterize independent and dose–response effects.
- Subgroup analyses demonstrating consistency across demographics and comorbidities.
Limitations
- Retrospective single-timepoint biomarker assessment susceptible to residual confounding.
- External validation and clinical impact analysis (e.g., decision thresholds) were not provided.
Future Directions: Prospective, multicenter validation and integration of ACAG into composite risk scores; assess whether ACAG-guided care pathways improve outcomes.
BACKGROUND: Albumin-corrected anion gap (ACAG) is closely associated with the prognosis of many critical illnesses. However, the prognostic value of ACAG in sepsis-associated liver injury (SALI) is poorly understood. We explored the association between ACAG and patient prognosis in individuals diagnosed with SALI. METHODS: Data from patients with SALI admitted to the intensive care unit (ICU) between 2008 and 2022 were retrospectively analyzed. ACAG was calculated based on the first measurement of the anion gap and albumin level within 24 h of admission. The optimal cutoff value for ACAG was established using R statistical software. Kaplan-Meier analysis was conducted to compare mortality risks between the two groups, while multivariable Cox proportional hazards regression models were employed to examine the association between ACAG and mortality risk in SALI patients. To assess a potential dose-response relationship, restricted cubic splines (RCS) were applied. Lastly, subgroup analyses were carried out to investigate the correlation between ACAG levels and prognosis across different patient populations. RESULTS: A total of 443 critically ill patients with SALI were included in the lower (n = 342) and higher ACAG (n = 101) groups based on ACAG levels. No statistically significant differences were observed between the two groups regarding age, sex, or ethnicity (P = 0.12, 0.84, and 0.85, respectively). However, patients in the higher ACAG group exhibited a greater propensity for developing respiratory failure. The rates of ICU, in-hospital, 14-day, 28-day, and 90-day mortality were significantly elevated in the higher ACAG group (all P < 0.001). Higher ACAG levels were significantly associated with an increased mortality risk at multiple time points (all P < 0.001). ACAG levels and mortality showed a significant linear relationship. The impact of ACAG on mortality risk remained consistent across subgroups defined by age, sex, hypertension, diabetes, and respiratory failure, with no significant interactions observed (all P for interaction > 0.05). CONCLUSION: ACAG serves as a significant independent predictor of mortality risk in patients with SALI. ACAG predicts both short-term mortality risk (such as ICU mortality) and long-term mortality risk (such as 90-day mortality). ACAG may serve as a valuable tool for prognostic assessment in patients with SALI with broad applicability.